Table 1 Baseline patient characters
Variable | No diabetes (n = 134) | Diabetes (n = 67) | p value |
|---|---|---|---|
Age, years | 48.8 ± 13.5 | 50.1 ± 13.8 | 0.53 |
Male, n | 78 (58.2%) | 41 (61.2%) | 0.69 |
Body mass index, kg/m2 | 25.9 ± 3.9 | 25.6 ± 3.7 | 0.69 |
Family history of HCM or SCD, n | 18 (13.4%) | 15 (22.4%) | 0.11 |
Heart rate, beats/min | 72.2 ± 9.3 | 72.7 ± 8.5 | 0.71 |
BNP, pg/mL | 1379.9 (636.3–2342.4) | 1605.5 (573.7–2726.3) | 0.71 |
Creatinine, umol/L | 77.3 ± 13.4 | 76.8 ± 14.8 | 0.83 |
Glomerular filtration rate, ml/min | 99.8 ± 20.2 | 93.7 ± 18.5 | 0.04 |
Hs-CRP, mg/L | 0.97 (0.40–1.80) | 1.30 (0.56–2.28) | 0.04 |
LDL, mmol/L | 2.6 ± 0.9 | 2.5 ± 0.6 | 0.31 |
HDL, mmol/L | 1.2 ± 0.5 | 1.16 ± 0.3 | 0.63 |
Comorbidities | |||
 Hypertension, n | 54 (40.3%) | 28 (41.8%) | 0.84 |
 Hyperlipemia, n | 28 (20.9%) | 15 (22.4%) | 0.81 |
Clinical presentation | |||
 Chest pain, n | 35 (26.1%) | 20 (29.9%) | 0.58 |
 Palpitation, n | 11 (8.2%) | 8 (11.9%) | 0.39 |
 Syncope, n | 14 (10.4%) | 8 (11.9%) | 0.75 |
 Atrial fibrillation, n | 16 (11.9%) | 19 (28.4%) | 0.004 |
Echocardiographic indices | |||
 LVEDD, mm | 41.8 ± 5.7 | 41.5 ± 4.5 | 0.70 |
 IVST, mm | 20.3 ± 5.6 | 20.0 ± 5.8 | 0.74 |
 Posterior wall, mm | 11.9 ± 2.4 | 12.2 ± 2.9 | 0.56 |
 LVEF,  % | 71.4 ± 5.6 | 71.3 ± 5.4 | 0.94 |
 IVST ≥ 30 mm, n | 11 (8.2%) | 4 (6.0%) | 0.57 |
 Moderate or severe MR | 24 (17.9%) | 7 (10.4%) | 0.17 |
Medical therapy | |||
 Beta-blockers, n | 99 (73.9%) | 50 (74.6%) | 0.91 |
 Calcium-channel blockers, n | 7 (5.2%) | 7 (10.4%) | 0.17 |
 ACEI/ARB, n | 17 (12.7%) | 8 (11.9%) | 0.88 |
 Statins, n | 14 (10.4%) | 11 (16.4%) | 0.23 |
 Insulin, n | – | 19 (28.4%) | – |
 Metformin, n | – | 39 (58.2%) | – |
 Acarbose, n | – | 12 (17.9%) | – |